Results 31 to 40 of about 5,889,184 (390)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark

Diagnostics, 2022
The impact of changes in diagnostic activity and treatment options on prostate cancer epidemiology remains a subject of debate. Newly published long-term survival outcomes may not represent contemporary patients and new perspectives are in demand.
Marc Casper Meineche Andersen, Hein Vincent Stroomberg, Klaus Brasso, John Thomas Helgstrand, Andreas Røder   +4 more
doaj   +1 more source

Prostate cancer incidence in Golestan province, Iran (2004) [PDF]

, 2008
Prostate cancer is the most common cancer in men and therefore represents a major problem in public health.The aim of this study was to find and evaluate province-specific estimate of incidence in males by age groups for prostate cancer in Golestan ...
Kabir, M.J., Marjani, A.
core   +1 more source

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]

, 2015
The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri, Alshaker, Heba, Muhammad, Aun, Pchejetski, Dmitri, Sacco, Keith, Winkler, Mathias   +5 more
core   +6 more sources

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness

Scientific Reports, 2017
Short tandem repeats (STRs) are repetitive sequences of a polymorphic stretch of two to six nucleotides. We hypothesized that STRs are associated with prostate cancer development and/or progression. We undertook RNA sequencing analysis of prostate tumors
John Lai, Leire Moya, Jiyuan An, Andrea Hoffman, Srilakshmi Srinivasan, Janaththani Panchadsaram, Carina Walpole, Joanna L. Perry-Keene, Suzanne Chambers, Australian Prostate Cancer BioResource, Melanie L. Lehman, Colleen C. Nelson, Judith A. Clements, Jyotsna Batra   +13 more
doaj   +1 more source

Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients

Prostate International, 2015
Purpose: To determine the incidence and clinical features of incidentally discovered prostate adenocarcinoma in patients undergoing radical cystoprostatectomy (CPT) for bladder cancer.
In-Chang Cho, Jeong Eun Kim, Sung Han Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Kang Hyun Lee   +7 more
doaj   +1 more source

Multiparametric magnetic resonance imaging of the prostate-a basic tutorial. [PDF]

, 2017
Prostate cancer is the second most common cause of cancer related death in the United States and the most commonly diagnosed malignancy in men. In general, prostate cancer is slow growing, though there is a broad spectrum of disease that may be indolent,
Cabarrus, Miguel C, Westphalen, Antonio C   +1 more
core   +1 more source

Cancer statistics for the year 2020: An overview

International Journal of Cancer, 2021
Our study briefly reviews the data sources and methods used in compiling the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics for the year 2020 and summarises the main results.
J. Ferlay, M. Colombet, I. Soerjomataram, D. Parkin, M. Piñeros, A. Znaor, F. Bray   +6 more
semanticscholar   +1 more source

WNT signalling in prostate cancer [PDF]

, 2017
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-
A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine   +166 more
core   +2 more sources

Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study

BJGP Open
Background: The UK has an informed choice testing policy for prostate cancer. The prostate-specific antigen (PSA) blood test is available for free to any man aged ≥50 years who requests it and has been informed of the harms and benefits.
Natalia Norori, Chiara de Biase, Yui Hang Wong, Sadie Robson Crabtree, Matt Cox, Esther Appleby, Andrew Seggie, Rachel Brown, Amy Rylance   +8 more
doaj   +1 more source